Cargando…

Cerebrovascular pathology in Down syndrome and Alzheimer disease

People with Down syndrome (DS) are at high risk for developing Alzheimer disease (AD) with age. Typically, by age 40 years, most people with DS have sufficient neuropathology for an AD diagnosis. Interestingly, atherosclerosis and hypertension are atypical in DS with age, suggesting the lack of thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Head, Elizabeth, Phelan, Michael J., Doran, Eric, Kim, Ronald C., Poon, Wayne W., Schmitt, Frederick A., Lott, Ira T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709935/
https://www.ncbi.nlm.nih.gov/pubmed/29195510
http://dx.doi.org/10.1186/s40478-017-0499-4
_version_ 1783282877135323136
author Head, Elizabeth
Phelan, Michael J.
Doran, Eric
Kim, Ronald C.
Poon, Wayne W.
Schmitt, Frederick A.
Lott, Ira T.
author_facet Head, Elizabeth
Phelan, Michael J.
Doran, Eric
Kim, Ronald C.
Poon, Wayne W.
Schmitt, Frederick A.
Lott, Ira T.
author_sort Head, Elizabeth
collection PubMed
description People with Down syndrome (DS) are at high risk for developing Alzheimer disease (AD) with age. Typically, by age 40 years, most people with DS have sufficient neuropathology for an AD diagnosis. Interestingly, atherosclerosis and hypertension are atypical in DS with age, suggesting the lack of these vascular risk factors may be associated with reduced cerebrovascular pathology. However, because the extra copy of APP leads to increased beta-amyloid peptide (Aβ) accumulation in DS, we hypothesized that there would be more extensive and widespread cerebral amyloid angiopathy (CAA) with age in DS relative to sporadic AD. To test this hypothesis CAA, atherosclerosis and arteriolosclerosis were used as measures of cerebrovascular pathology and compared in post mortem tissue from individuals with DS (n = 32), sporadic AD (n = 80) and controls (n = 37). CAA was observed with significantly higher frequencies in brains of individuals with DS compared to sporadic AD and controls. Atherosclerosis and arteriolosclerosis were rare in the cases with DS. CAA in DS may be a target for future interventional clinical trials.
format Online
Article
Text
id pubmed-5709935
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57099352017-12-06 Cerebrovascular pathology in Down syndrome and Alzheimer disease Head, Elizabeth Phelan, Michael J. Doran, Eric Kim, Ronald C. Poon, Wayne W. Schmitt, Frederick A. Lott, Ira T. Acta Neuropathol Commun Research People with Down syndrome (DS) are at high risk for developing Alzheimer disease (AD) with age. Typically, by age 40 years, most people with DS have sufficient neuropathology for an AD diagnosis. Interestingly, atherosclerosis and hypertension are atypical in DS with age, suggesting the lack of these vascular risk factors may be associated with reduced cerebrovascular pathology. However, because the extra copy of APP leads to increased beta-amyloid peptide (Aβ) accumulation in DS, we hypothesized that there would be more extensive and widespread cerebral amyloid angiopathy (CAA) with age in DS relative to sporadic AD. To test this hypothesis CAA, atherosclerosis and arteriolosclerosis were used as measures of cerebrovascular pathology and compared in post mortem tissue from individuals with DS (n = 32), sporadic AD (n = 80) and controls (n = 37). CAA was observed with significantly higher frequencies in brains of individuals with DS compared to sporadic AD and controls. Atherosclerosis and arteriolosclerosis were rare in the cases with DS. CAA in DS may be a target for future interventional clinical trials. BioMed Central 2017-12-01 /pmc/articles/PMC5709935/ /pubmed/29195510 http://dx.doi.org/10.1186/s40478-017-0499-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Head, Elizabeth
Phelan, Michael J.
Doran, Eric
Kim, Ronald C.
Poon, Wayne W.
Schmitt, Frederick A.
Lott, Ira T.
Cerebrovascular pathology in Down syndrome and Alzheimer disease
title Cerebrovascular pathology in Down syndrome and Alzheimer disease
title_full Cerebrovascular pathology in Down syndrome and Alzheimer disease
title_fullStr Cerebrovascular pathology in Down syndrome and Alzheimer disease
title_full_unstemmed Cerebrovascular pathology in Down syndrome and Alzheimer disease
title_short Cerebrovascular pathology in Down syndrome and Alzheimer disease
title_sort cerebrovascular pathology in down syndrome and alzheimer disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709935/
https://www.ncbi.nlm.nih.gov/pubmed/29195510
http://dx.doi.org/10.1186/s40478-017-0499-4
work_keys_str_mv AT headelizabeth cerebrovascularpathologyindownsyndromeandalzheimerdisease
AT phelanmichaelj cerebrovascularpathologyindownsyndromeandalzheimerdisease
AT doraneric cerebrovascularpathologyindownsyndromeandalzheimerdisease
AT kimronaldc cerebrovascularpathologyindownsyndromeandalzheimerdisease
AT poonwaynew cerebrovascularpathologyindownsyndromeandalzheimerdisease
AT schmittfredericka cerebrovascularpathologyindownsyndromeandalzheimerdisease
AT lottirat cerebrovascularpathologyindownsyndromeandalzheimerdisease